Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Gilead Sciences 7.803, Vertex Pharmaceuticals 3.334.
Gilead Sciences vs Vertex Pharmaceuticals Net Worth and Market Cap
Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) are peers in Healthcare. Gilead Sciences reported revenue of $7.8B as of Q2 2026, compared with $3.3B for Vertex Pharmaceuticals. Gilead Sciences leads on revenue.
Gilead Sciences's gross margin is 79.8% versus 85.3% for Vertex Pharmaceuticals. Gilead Sciences's net margin is -134.5% versus 33.0% for Vertex Pharmaceuticals.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Gilead Sciences, Vertex Pharmaceuticals.| Metric | Gilead Sciences | Vertex Pharmaceuticals |
|---|---|---|
| Market Cap | - | - |
| Revenue | $7.80B | $3.33B |
| Cost of Revenue | $1.58B | $489.00M |
| Gross Profit | $6.22B | $2.85B |
| Operating Income | $-10.39B | $1.25B |
| Net Income | $-10.50B | $1.10B |
| R&D Expense | $1.76B | $994.00M |
| Earnings Per Share | -$8.45 | $4.31 |
| Gross Margin | 79.8% | 85.3% |
| Operating Margin | -133.2% | 37.4% |
| Net Profit Margin | -134.5% | 33.0% |
| Free Cash Flow | $3.69B | $1.01B |
| Cumulative Free Cash Flow | $155.83B | $17.24B |
| Operating Cash Flow | $3.57B | $1.13B |
| Cash & Equivalents | $3.18B | $6.14B |